Related references
Note: Only part of the references are listed.Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
May Daher et al.
BLOOD (2021)
Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity
Hind Rafei et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer
May Daher et al.
CANCER DISCOVERY (2021)
Immunogenicity of CAR T cells in cancer therapy
Dimitrios L. Wagner et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
Karen Slattery et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Lucila N. Kerbauy et al.
CLINICAL CANCER RESEARCH (2021)
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Jay Y. Spiegel et al.
NATURE MEDICINE (2021)
Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy
Chloe Choi et al.
STEM CELL RESEARCH & THERAPY (2021)
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy
Rafet Basar et al.
CELL REPORTS (2021)
CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro
Minh Tuyet Ma et al.
FRONTIERS IN IMMUNOLOGY (2021)
Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
Paolo Strati et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells
Hila Shaim et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Huang Zhu et al.
BLOOD (2020)
Virus-specific T-cell therapies for patients with primary immune deficiency
Michael D. Keller et al.
BLOOD (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts
Yu Yang Ng et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence
Sean J. Judge et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
Margery Gang et al.
BLOOD (2020)
Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity
Huang Zhu et al.
CELL STEM CELL (2020)
B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors
Zongliang Zhang et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
A single-cell atlas of the peripheral immune response in patients with severe COVID-19
Aaron J. Wilk et al.
NATURE MEDICINE (2020)
A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)
Carlos Bachier et al.
BLOOD (2020)
CD33 Targeting Primary CAR-NK Cells Generated By CRISPR Mediated Gene Insertion Show Enhanced Anti-AML Activity
Meisam Naeimi Kararoudi et al.
BLOOD (2020)
Natural killer cell metabolism
Takumi Kobayashi et al.
MOLECULAR IMMUNOLOGY (2019)
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Takahiro Kamiya et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
Yingxi Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
Katherine D. Cummins et al.
HAEMATOLOGICA (2019)
What Defines NK Cell Functional Fate: Phenotype or Metabolism?
Sophie M. Poznanski et al.
FRONTIERS IN IMMUNOLOGY (2019)
Exploring NKG2D and BCMA-CAR NK-92 for Adoptive Cellular Therapy to Multiple Myeloma
Elena Maroto Martin et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance
Xiaohu Zheng et al.
NATURE IMMUNOLOGY (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies
Jode P. Goodridge et al.
BLOOD (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
Lauren C. Fleischer et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
Robert Weinkove et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
Immunometabolism and natural killer cell responses
Katie L. O'Brien et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells
Huda Salman et al.
JOURNAL OF CANCER (2019)
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
E. Liu et al.
LEUKEMIA (2018)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Rohtesh S. Mehta et al.
FRONTIERS IN IMMUNOLOGY (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy
Muharrem Muftuoglu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
Kerry S. Campbell et al.
FRONTIERS IN IMMUNOLOGY (2018)
NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells
Alejandra Leivas et al.
BLOOD (2018)
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment
Arabella Young et al.
CANCER RESEARCH (2018)
Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells
Stephan Kloss et al.
HUMAN GENE THERAPY (2017)
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation
Ifigeneia Tzannou et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR Cas9 nuclease off-targets
Shengdar Q. Tsai et al.
NATURE METHODS (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
Kevin G. Pinz et al.
ONCOTARGET (2017)
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
Veronika Kremer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity
Frank Cichocki et al.
CANCER RESEARCH (2017)
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
Arabella Young et al.
CANCER CELL (2016)
CIS is a potent checkpoint in NK cell-mediated tumor immunity
Rebecca B. Delconte et al.
NATURE IMMUNOLOGY (2016)
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Rizwan Romee et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Repression of GSK3 restores NK cell cytotoxicity in AML patients
Reshmi Parameswaran et al.
NATURE COMMUNICATIONS (2016)
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
Kevin H. Chen et al.
ONCOTARGET (2016)
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Katrin Toepfer et al.
JOURNAL OF IMMUNOLOGY (2015)
Activation-Specific Metabolic Requirements for NK Cell IFN-γ Production
Molly P. Keppel et al.
JOURNAL OF IMMUNOLOGY (2015)
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Xiao-Hui Zhang et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Shengdar Q. Tsai et al.
NATURE BIOTECHNOLOGY (2015)
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
Jianfeng Han et al.
SCIENTIFIC REPORTS (2015)
CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells
Ana Stojanovic et al.
JOURNAL OF IMMUNOLOGY (2014)
Transfection of chimeric anti-CD 138 gene enhances natural killer cell activation and killing of multiple myeloma cells
Hua Jiang et al.
MOLECULAR ONCOLOGY (2014)
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
J. Chu et al.
LEUKEMIA (2014)
Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy
Isabela Pedroza-Pacheco et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors
Jing Ni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers
Joseph R. Dobosy et al.
BMC BIOTECHNOLOGY (2011)
Costimulation by chimeric antigen receptors revisited: the T cell antitumor response benefits from combined CD28-OX40 signalling
Andreas A. Hombach et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CDI9-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Michael C. Jensen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Cytokine-induced memory-like natural killer cells
Megan A. Cooper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
C Imai et al.
LEUKEMIA (2004)
NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway
DD Billadeau et al.
NATURE IMMUNOLOGY (2003)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor
J Maher et al.
NATURE BIOTECHNOLOGY (2002)
Share Paper
